NCT06510309
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +10 more
- Locations
-
- Beth Israel Deaconess Medical Center Boston, Massachusetts, United States
Clinical trial condition
Marginal Zone Lymphoma
Explore clinical trials studying Marginal Zone Lymphoma. Study availability and eligibility vary by location and protocol.
114 public trials
41 recruiting studies
Marginal Zone Lymphoma trial results
NCT07441993
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
- Locations
-
- Nanfang Hospital, Southern Medical University Guangzhou, Guangdong, China
- Henan Cancer Hospital Zhengzhou, Henan, China
- Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan, Hubei, China
- Xiangyang Central Hospital Xiangyang, Hubei, China
NCT06151730
- Conditions
- Blood Protein Disorders, Cardiovascular Diseases, Chronic Disease, +30 more
- Locations
-
- Mayo Clinic in Rochester Rochester, Minnesota, United States
Recruiting
Optimize Study - Orelabrutinib Combined With BR/G in Untreated Marginal Zone Lymphoma (MZL)
NCT06504940
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
- Locations
-
- The First Affiliated Hospital ，Zhejiang University School of Medicine Hangzhou, Zhejiang, China
NCT04186520
- Conditions
- Central Nervous System Lymphoma, Chronic Disease, Chronic Lymphocytic Leukemia (CLL), +28 more
- Locations
-
- Medical College of Wisconsin and Froedtert Hospital Milwaukee, Wisconsin, United States
Recruiting
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
NCT05990465
- Conditions
- Burkitt Lymphoma, DNA Virus Infections, Diffuse Large B Cell Lymphoma, +23 more
- Locations
-
- Froedtert & the Medical College of Wisconsin Milwaukee, Wisconsin, United States
Recruiting
Epco, Zanu, Ritux for R/R FL or MZL
NCT06563596
- Conditions
- Follicular Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +14 more
- Locations
-
- Dana-Farber Cancer Institute Boston, Massachusetts, United States
- Memorial Sloan Kettering Cancer Center New York, United States
- The Ohio State University Wexner Medical Center Columbus, Ohio, United States
NCT07029217
- Conditions
- Follicular Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +11 more
- Locations
-
- Memorial Sloan Kettering Basking Ridge (All Protocol Activities) Basking Ridge, New Jersey, United States
- Memorial Sloan Kettering Monmouth (All Protocol Activities) Middletown, New Jersey, United States
- Memorial Sloan Kettering Bergen (All Protocol Activities) Montvale, New Jersey, United States
- Memorial Sloan Kettering Suffolk - Commack (All Protocol Activities) Commack, New York, United States
Recruiting
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
NCT04775745
- Conditions
- Blood Protein Disorders, CLL/SLL, Cardiovascular Diseases, +28 more
- Locations
-
- Duke Univerisity Durham, North Carolina, United States
- University of Cincinnati Cincinnati, Ohio, United States
- Ohio State University Columbus, Ohio, United States
- Huntsman Cancer Institute, University of Utah Salt Lake City, Utah, United States
NCT04883437
- Conditions
- Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, +18 more
- Locations
-
- Emory University Hospital/Winship Cancer Institute Atlanta, Georgia, United States